

# Tsukasa Hasegawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1622166/publications.pdf>

Version: 2024-02-01

10  
papers

120  
citations

1478280

6  
h-index

1474057

9  
g-index

13  
all docs

13  
docs citations

13  
times ranked

167  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. <i>BMC Cancer</i> , 2020, 20, 207.                                       | 1.1 | 26        |
| 2  | Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 6851-6857.  | 0.5 | 24        |
| 3  | Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. <i>Lung Cancer</i> , 2020, 144, 71-75.   | 0.9 | 21        |
| 4  | Predictive factors for relapse of cryptogenic organizing pneumonia. <i>BMC Pulmonary Medicine</i> , 2019, 19, 10.  | 0.8 | 20        |
| 5  | Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 2997-3003.   | 0.6 | 11        |
| 6  | Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. <i>Thoracic Cancer</i> , 2020, 11, 2465-2472.   | 0.8 | 7         |
| 7  | Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. <i>International Journal of Clinical Oncology</i> , 2020, 25, 67-73.  | 1.0 | 6         |
| 8  | Mild Lung Tuberculosis in a Patient Suffering from Status Epilepticus Caused by the Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH). <i>Internal Medicine</i> , 2017, 56, 429-433.   | 0.3 | 3         |
| 9  | Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100249. | 0.7 | 1         |
| 10 | Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 507-514.  | 1.0 | 1         |